GI DISEASE

At Sterling Bioanalytics, we specialize in delivering advanced statistical analysis and data solutions for clinical trials in gastrointestinal (GI) disorders. Our team partners with pharmaceutical and biotech companies to support the development of safe, effective therapies for complex GI conditions.

From protocol design to final reporting, our statistical services empower GI clinical trials with the rigor, flexibility, and insight needed to drive innovation and improve patient outcomes.

Our areas of expertise:

🟣 Opioids induced constipation-

Opioid-induced constipation remains one of the most common and challenging side effects of long-term opioid therapy. We provide expert statistical guidance for trials evaluating new pharmacologic treatments, behavioral interventions, and combination therapies aimed at managing OIC. Our services support clear endpoint definition, real-time data monitoring, and compliance with regulatory expectations.

🟣 Crohn’s disease-

Crohn’s disease presents wide variability in patient response and disease progression. Our statistical expertise helps sponsors navigate this complexity through:

• Adaptive trial design

• Biomarker and subgroup analyses

• Longitudinal modeling of inflammatory markers and symptom scores
  We bring precision and clarity to data from early phase through post-marketing studies.

🟣 Ulcerative colitis-

Clinical trials in UC demand a nuanced approach to patient stratification, endpoint evaluation, and flare/remission tracking. We support full-service analytics for trials targeting:

• Mucosal healing

• Symptom relief and quality of life

• Biologic and small-molecule treatments
  Our team ensures data accuracy and meaningful interpretation to guide successful product development and regulatory submission.